SCHEMBL509882

SCHEMBL509882

COc1cc2cc(-c3ccccc3C)nc(N)c2cc1OC

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.64
PDPK1 O15530 2/20 0.49
HSP90AA1 P07900 2/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAC1 P63000 3/20 0.46
POLB P06746 2/20 0.46
GAA P10253 1/20 0.46
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
DHFR P00374 3/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HSP90AB1 P08238 1/20 0.43
TLR8 Q9NR97 1/20 0.42
DNMT1 P26358 1/20 0.41
EHMT2 Q96KQ7 1/20 0.41
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509287 0.85 RAD52 (0.59) RAD52PDPK1HSP90AA1MEN1KMT2A
SCHEMBL510224 0.81 SMN1; SMN2 (0.58) RAD52PDPK1MEN1KMT2ARAC1
SCHEMBL11377936 0.79 DHFR (0.49) HSP90AA1MEN1KMT2APOLBDHFR
SCHEMBL509116 0.78 DHFR (0.46) RAD52HSP90AA1MEN1KMT2AGAA
SCHEMBL697020 0.78 DHFR (0.46) RAD52HSP90AA1MEN1KMT2AGAA
SCHEMBL3321121 0.77 RAC1 (0.59) RAD52PDPK1HSP90AA1MEN1KMT2A
SCHEMBL12070505 0.77 RAD52 (0.53) RAD52PDPK1MEN1KMT2ARAC1
Hydrochloric Acid SCHEMBL509568 0.77 DHFR (0.44) RAD52HSP90AA1MEN1KMT2AGAA
SCHEMBL509476 0.76 HSP90AA1 (0.56) RAD52PDPK1HSP90AA1MEN1KMT2A
SCHEMBL509907 0.76 HSP90AA1 (0.56) RAD52PDPK1HSP90AA1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 RAD52 542/4885PDPK1 2830/4885HSP90AA1 3160/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 RAD52 542/4885PDPK1 2830/4885HSP90AA1 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.